High Utilization Seen as GMP Issue Behind Cancer Drug Shortages
This article was originally published in The Gold Sheet
A lack of manufacturing capacity blamed for sterile injectable oncology drug shortages can be viewed as a GMP compliance issue, FDA official says, pointing to Section 211 process validation requirements. HHS analysis links the shortages to excessive utilization rates at generics firms.
You may also be interested in...
How FDA, health care providers, and Pfizer and other drug makers are responding to a shortage of emergency medicines from the fragile, overstressed US sterile injectables sector.
Hiring travails, inspection pre-announcement, lack of translators highlighted in congressional hearing on FDA foreign inspections.
Singapore recalls trigger international reaction as metformin is added to growing list of chronic medications found to contain NDMA.